About the Company
We do not have any company description for First Wave BioPharma, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FWBI News
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
During the conference, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors, showcasing the company’s business and clinical development ...
First Wave BioPharma Completes Merger Deal With ImmunogenX Adding Phase 3-Ready Candidate For Celiac Disease
In December, First Wave BioPharma entered a non-binding term sheet to sell its Niclosamide program for treating inflammatory ...
Here's Why First Wave BioPharma (FWBI) Is a Great 'Buy the Bottom' Stock Now
Shares of First Wave BioPharma, Inc. (FWBI) have been struggling lately and have lost 6.6% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean ...
First Wave BioPharma Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Why First Wave BioPharma Shares Are Tanking Today
First Wave BioPharma Inc (NASDAQ: FWBI) shares are plummeting after the company reported topline data from Phase 2 RESERVOIR trial of FW-COV, oral formulation of niclosamide, for COVID-19-related ...
First Wave BioPharma Stock (NASDAQ:FWBI), Quotes and News Summary
President & CEO of First Wave BioPharma, Inc. (NASDAQ: FWBI) was recently a guest on Benzinga’s All-Access.
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical ...
First Wave BioPharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
First Wave BioPharma Inc.
1 Day FWBI -1.34% DJIA -0.77% Russell 2K -1.27% Health Care/Life Sciences 0.12% ...
First Wave BioPharma, Inc. (FWBI)
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in ...
Loading the latest forecasts...